Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales Cambridge, UK, 05 August 2020: CN Bio, a leading
CN Bio and Cambridge University identify novel regulatory pathway driving NASH
Paper published in Nature Metabolism demonstrates novel pathway regulating the underlying mechanism of liver fibrosis
CN Bio Innovations raises $9 million USD (c. £6.9 million GBP)
Investment will support commercial development in key markets, US and Europe Funding led by CITIC Securities Investment and supported by existing
NASH drug discovery service launched at AASLD
Leading bioengineering company CN Bio has launched a fee for service program providing Human Organ-on-Chip data to scientists studying non-alcoholic
Sydney’s AXT offers Organ-on-Chip systems in Asia Pacific region
Organ-on-Chip specialist CN Bio has signed a distribution agreement with Sydney-based AXT Pty. Ltd., Australia’s leading supplier of high technology
CN Bio to bring 10 organs together on a chip
London Organ-on-Chip specialist CN Bio today announced it has secured an exclusive license to technology from the Massachusetts Institute of
PhysioMimix® Human 3D Cell Culture wins Lab Innovation 2018 Award
The PhysioMimix® benchtop 3D cell culture system from CN Bio has won the Innovation Award at the UK’s largest laboratory event, held at the NEC
CN Bio Innovations’ Board names David Hughes as next Chief Executive Officer
London, UK, 19 July 2018: CN Bio Innovations Limited today announced that its Board of Directors has accepted the resignation of Dr Emma Sceats as CEO
CN Bio launches PhysioMimix benchtop Human-Body-on-a-Chip device
London, UK, 23 May 2018: CN Bio Innovations Limited today launched PhysioMimix, a printer-sized device which allows scientist to conduct organ-on-chip